Company Now Exclusively Focused on Development and Commercialization of Abecma CAMBRIDGE, Mass. / Apr 01, 2024 / Business Wire / 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees... Read More